Efficacy and safety of Metoprolol Succinate prolonged-release tablet in patients with mild to moderate hypertension

Study identifier:D4025L00006

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

An open-label, non-comparative, multi-centre study to evaluate the Efficacy and safety of Metoprolol Succinate prolonged-release tablet (Betaloc Zok) in patients with mild to moderate essential hypertension

Medical condition

hypertension

Phase

Phase 4

Healthy volunteers

Study drug

metoprolol succinate prolonged-release tablet and felodipine

Sex

All

Actual Enrollment

310

Study type

Interventional

Age

18 Years - 70 Years

Date

Study Start Date: 01 Oct 2005

Primary Completion Date: 01 Apr 2006

Study Completion Date: 01 May 2006

Study design

Allocation: N/A
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals

Collaborators

Inclusion and exclusion criteria

No locations available

Arms	Assigned Interventions
Experimental: 1 The patients with mild to moderate essential hypertension	Drug: metoprolol succinate prolonged-release tablet and felodipine a regimen that starts with metoprolol succinate prolonged-release tablet 47.5mg once daily, orally and allows for dose escalation to 95mg once daily, orally at 4 weeks if not controlled; at week 8 allows for the addition of felodipine sustained release tablet 5mg once daily, orally Other Name: Betaloc ZOK and Plendil

Documents available

https://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&studyid=1408&filename=CSR-D4025L00006.pdf
Download
CSR-D4025L00006.pdf
Download
Trial Results Summaries
Available here

Contacts

Contact

AstraZeneca Clinical Study Information

800-236-9933

information.center@astrazeneca.com

Investigators

Principal Investigator

Lisheng Liu

BeiJing Hypertension League